Global Pneumococcal Vaccines Market to Surpass US$ 13,194.3 Million by 2026: CohPosted by Pareesh on February 11th, 2019 Healthcare facilities are looking forward to expand their facilities with advanced technologies to create innovative and cost-effective solutions to address barriers to universal vaccination For instance, in April 2016, Glaxo Smith Kline (GSK) and Vodafone collaborated to provide smartphones with an app to various healthcare facilities in northern Mozambique, Africa for a period of one year. The program received funds from GAVI and United States Agency for International Development (USAID) under mVacciNation pilot program. The app enables these healthcare facilities to report regularly on vaccine stock levels and refrigerator temperatures, thereby improving critical supply chain and cold chain management. Furthermore, it helps health workers to register patients, view their vaccination histories, and also allows to send reminders to registered patients for their next vaccination. Get Exclusive Sample Copy @ https://www.coherentmarketinsights.com/insight/request-sample/2295 Increasing collaborations among key players to develop and introduce new pneumococcal vaccines and ongoing clinical trial studies on pneumococcal vaccine are expected to drive growth of the pneumococcal vaccines market. For instance, in April 2018, Merck & Co, Inc. initiated two Phase III studies of PCV-15 (V114), an investigational polyvalent conjugate vaccine for the prevention of pneumococcal disease. Furthermore, in February 2017, Astellas Pharma Inc. and Affinivax, Inc. signed an exclusive worldwide license agreement to develop and commercialize a vaccine targeting Streptococcus pneumoniae. This partnership would utilize Affinivax’s proprietary vaccine technology platform – Multiple Antigen Presenting System (MAPS) to develop a novel vaccine. Key players operating in the pneumococcal vaccines market include, Pfizer, Inc., Merck & Co. Inc., and GlaxoSmithKline plc. Pharmaceutical companies are reluctant to invest in production of new vaccines, owing to very less returns. Therefore, vendors are focused on joining Advance Market Commitment (AMC), an innovative financing program. Under AMC, international agencies pay a premium above the incremental production cost for initial doses sold to emerging economies in exchange of continuous supply of vaccines from vendors at sustainable prices for long term. In 2010, Pfizer entered into the AMC program and agreed to supply 300 Mn doses of PCV13 for pneumococcal disease. Subsequently, Pfizer entered into two additional agreements with the AMC expanding its commitment with an additional 440 Mn doses, for a total commitment of 740 Mn doses of PCV13 vaccine until 2025. Download PDF Brochure of This Business Research Report: https://www.coherentmarketinsights.com/insight/request-pdf/2295 Moreover, in 2015, Pfizer reduced prices of four new dose vial presentations of PCV13, which was expected to be introduced under the AMC program in 2016. The prices were reduced by 20% per-dose i.e., from US$ 3.30 per dose to US$ 3.10 per dose. About Coherent Market Insights: Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity. Contact Us: Mr. Shah Like it? Share it! More by this author |